As of November 6, 2026, Halozyme Therapeutics Inc is a publicly traded company (Nasdaq: HALO); its largest reported holder is BlackRock, with 10.2% on Schedule 13G/A of July 17, 2025, then Vanguard (5.21%). The largest insider holding is Helen Torley, the chief executive and president, with 767,780 shares (0.67% of shares outstanding), per Form 4 of October 8, 2026 (Schedule 13G/A, July 17, 2025).
Is this your company?
About to sign with, pay or invest in Halozyme Therapeutics Inc? See the free Snapshot first.
Free to see. No signup.
Is Halozyme Therapeutics Inc a real, registered company?
- Halozyme Therapeutics Inc files with the SEC under CIK 1159036 (its SEC filings).
- Its shares are listed under the ticker HALO on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Halozyme Therapeutics Inc in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is James Daly (Form 8-K filed 2026-09-30). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Vanguard (filed 2026-04-30).
Who are Halozyme Therapeutics Inc's owners and officers?
Halozyme Therapeutics Inc: incorporated in Delaware; business address in San Diego, California; industry Biological Products, (No Diagnostic Substances) (Form D, 2026-09-30).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-04-30 | Vanguard Capital Management | 5.21% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2025-07-17 | Blackrock, Inc. | 10.2% |
Questions about who owns Halozyme Therapeutics Inc
Who owns Halozyme Therapeutics Inc?
On this page, 2 holders' latest ownership filings report 5% or more of Halozyme Therapeutics Inc: Blackrock, Inc. (10.2%, Schedule 13G/A, filed 2025-07-17) and Vanguard Capital Management (5.21%, Schedule 13G, filed 2026-04-30).
Who are the largest shareholders of Halozyme Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Halozyme Therapeutics Inc on this page are Blackrock, Inc. (10.2%) and Vanguard Capital Management (5.21%).
When did Blackrock, Inc. buy into Halozyme Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Blackrock, Inc. on this page is the Schedule 13G/A, filed 2025-07-17, reporting 10.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Halozyme Therapeutics Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Halozyme Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Halozyme Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-30 | James Daly | appointed | ||
| Form 8-K, 2026-08-18 | Dannielle Appelhans | appointed | ||
| Form 8-K, 2026-04-30 | Darren Snellgrove | Chief Financial Officer | appointed | 2026-06-08 |
Which insiders own Halozyme Therapeutics Inc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 767,780 shares (0.67% of shares outstanding) (Form 4, 2026-10-08).
- , a director: 183,035 shares (0.16% of shares outstanding) (Form 4, 2024-12-03).
- , the senior vice president and chief technical officer: 173,756 shares (0.15% of shares outstanding) (Form 4, 2025-02-27).
- , a director: 53,609 shares (0.05% of shares outstanding) (Form 4, 2026-10-02).
- , the senior vice president and chief legal officer: 49,929 shares (0.04% of shares outstanding) (Form 4, 2026-06-15).
Shares outstanding: 114,010,000 as of 2026-10-31, from the company's latest SEC cover page.
How much has Halozyme Therapeutics Inc raised?
No fundraising or offering filing from Halozyme Therapeutics Inc is on file with us.
Keep reading
More on Halozyme Therapeutics Inc and the records around it.
Halozyme Therapeutics Inc elsewhere on the record
- Leadership changes Aug 2026
Companies that share a holder
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/halozyme-therapeutics